-
Stephan Moll, MD writes (last updated: Sept 9th, 2020)… Background: Hospitalized patients with COVID-19 are at increased risk for thrombosis – DVT, PE, and may be pulmonary micro-vascular thrombosis that possibly contributes to respiratory failure; arterial events appear to occur less commonly. Scientific/clinical data on prevalence of thrombosis, best prevention, and optimal therapy are limited.
-
Certain pain medications increase the risk of bleeding in patients on warfarin (coumadin®, Jantoven). Two mechanism can be at play: (1) non-steroidal pain medications (NSAIDs = non-steroidal anti-inflammatory drugs) may lead to gastritis which can lead to bleeding into the stomach, made worse by being on “blood thinners”, and (2) pain medications taken on a
-
Evaluation Anticoagulants often increase the amount of bleeding during menses and sometimes the number of days that a woman bleeds. However, this does not happen in every woman. In general, the more vaginal bleeding a woman has, the more cramping she experiences. Since warfarin may increase the vaginal bleeding
-
Evaluation Warfarin (coumadin®, Janotven®) and other blood thinners often increase the amount of bleeding during menses and sometimes the number of days that a woman bleeds. However, this does not happen in everyone – in some women there is no change in the bleeding pattern. In general, the more vaginal bleeding a woman has, the
-
The new oral anticoagulant Pradaxa® (Dabigatran) was approved by the FDA on October 20th, 2010 [ref 1,2]. As of Feb 3rd, 2012, Pradaxa® is only FDA approved for use in patients with atrial fibrillation. It is not approved yet for patients with DVT and PE.
-
Background and Summary Long distance travel, either by plane, car, bus or train, is a slight risk factor for DVT (deep vein thrombosis) and PE (pulmonary embolism). The risk is low. However, there are some people who are at higher risk. In these people compression stockings and/or an injection of a low-dose “blood thinner” (low
-
Background and summary Quite a few patients on warfarin have unstable, i.e. significantly fluctuating INRs, making warfarin therapy quite cumbersome. The cause of such fluctuations is often not clear. However, the following causes should be considered. Solutions how to deal with fluctuating INRs are also listed below.
-
Background and Consensus Guidelines No general consensus exists as to which patients with blood clots and which family members should be tested for thrombophilias. At least five guidelines or consensus statements exist (ref 1-5). They vary markedly in their recommendations as to who should be tested and who not,
-
Background, anatomy Arteries are the blood vessels that lead blood away from the heart into the periphery, i.e. to the extremities, the brain, the abdominal and pelvic organs. They deliver oxygen to organs and muscles. Veins lead the blood back to the heart, from where it flows into the lung to take up fresh oxygen.
-
Clot Connect is a collaborative outreach project led by the University of North Carolina Blood Clot Outreach Program. Clot Connect engages community partners to develop and deliver blood clot education programs for both patients and health care professionals. The progress: The Clot Connect website is now online, accessible at http://www.clotconnect.org. This format will be the
-
A common question from patients and dentists is whether warfarin needs to be interrupted at times of dental procedures, such as cleaning or pulling of teeth or root canals. Medical publications and recommendations from the dental community outlining best management of patients on warfarin exist (ref 1-6). However, even though evidence suggests that stopping warfarin for
A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center
Clot Connect 